Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus with cisplatin and gemcitabine for advanced urothelial cancer
ISRCTN31546330Phase 2Completed
- Sponsor
- Cardiff University
- Start
- Jul 2008
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus, cisplatin and gemcitabine in transitional cell carcinoma (TCC), sponsored by Cardiff University. Primary endpoints: Safety: dose-limiting toxicities and maximum tolerated dose, Recommended phase II dose and 1 more. Started Jul 2008; status: completed.
02
Drugs
temsirolimuscisplatingemcitabine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ISRCTN31546330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31546330.